Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune and Targeted Combination Therapies in First Line Metastatic RCC (U03A)
NCT04626479Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, lenvatinib, belzutifan, quavonlimab, favezelimab and 1 more in renal cell carcinoma (RCC) (5 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events at 43 months and 2 more. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04626479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626479.